Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed
Management of Lower Urinary Tract Dysfunction in Multiple Sclerosis: A Systematic Review and Turkish Consensus Report.
Implications for multiple sclerosis in the era of the Affordable Care Act: the shifting managed care landscape.
Oral contraceptives combined with interferon β in multiple sclerosis.
Cortical Lesions in Multiple Sclerosis: Clinical Relevance for a Hidden Disease Burden.
Mitochondrial DNA T4216C and A4917G variations in multiple sclerosis.
Current and Emerging Therapies for Multiple Sclerosis.
Disease exacerbation after rituximab induction in neuromyelitis optica.
[Locomotive syndrome and Frailty. Vitamin D and Frailty].
Depletion of brain functional connectivity enhancement leads to disability progression in multiple sclerosis: A longitudinal resting-state fMRI study.
A rare case of oligoastrocytoma with atypical symptoms initially diagnosed as multiple sclerosis: A case report.
Pain in acquired inflammatory demyelinating polyneuropathies.
Oxidative injury in multiple sclerosis cerebellar grey matter.
Anti-aquaporin 4 antibody-positive acute disseminated encephalomyelitis.
Optimal attenuation of experimental autoimmune encephalomyelitis by intravenous immunoglobulin requires an intact interleukin-11 receptor.
Mesenchymal stem cells attenuate MRI-identifiable injury, protect white matter, and improve long-term functional outcomes after neonatal focal stroke in rats.
Pediatric inflammatory diseases. Part I: multiple sclerosis.
The Fluctuating Natural Course of CCSVI in MS Patients and Controls, a Prospective Follow-Up.
Botulinum toxin type A in cerebellar tremor caused by multiple sclerosis.
Cost-Utility of Fingolimod Compared With Dimethyl Fumarate (Dmf) In Highly Active Relapsing Remitting Multiple Sclerosis (Rrms) In England: Comparison of A Markov and Discrete Event Simulation Model.
Oligodendrocyte progenitor programming and reprogramming: Toward myelin regeneration.
Reactivity to AQP4 epitopes in relapsing-remitting multiple sclerosis.
Teriflunomide for the treatment of relapsing-remitting multiple sclerosis: patient preference and adherence.
Association between perceived fatigue and gait parameters measured by an instrumented treadmill in people with multiple sclerosis: a cross-sectional study.
A case of neuromyelitis optica spectrum disorder associated with a limited cutaneous systemic sclerosis and Sjögren syndrome.
Mice with a deletion of the major central myelin protein exhibit hypersensitivity to noxious thermal stimuli: involvement of central sensitization.
Pages
« first
‹ previous
…
669
670
671
672
673
674
675
676
677
…
next ›
last »